Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG | Grabenstrasse 11A, 8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, 2 November 2023
We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.
TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.
Read moreThe European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.
Read moreThe Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.
Read more
